GLOBAL COMPANION DIAGNOSTICS MARKET 2022-2028

Description

MARKET OUTLOOK

Based on CRI’s report, the global companion diagnostics market is projected to progress with a CAGR of 12.84% during the forecast period 2022-2028.
The prominent factors fueling the global market’s growth include a surge in medication reaction incidence, increasing cancer cases, and the growing use of precision medicines. Additionally, the ongoing research and investments in next generation gene-sequencing are expected to create affluent opportunities for the market.
However, a weak reimbursement framework and common cases of leakage in oncology companion diagnostics are expected to restrict the studied market’s growth over the forecast period.

REGIONAL OUTLOOK

The global companion diagnostics market covers North America, Asia-Pacific, Latin America, Europe, and the Middle East and Africa regions.
The Asia-Pacific is anticipated to emerge as the fastest-growing region over the forecast period. The region’s growth can be attributed to the tremendous growth in precision medicine technology. Moreover, initiatives undertaken to promote the R&D of precision medicine are supporting the market’s growth. In this regard, diagnostic and pharma companies are collaborating to offer an international platform to facilitate access to precision medicine. Thus, as mentioned above, these factors are expected to widen the scope and growth of the companion diagnostics market in the upcoming years.

COMPETITIVE OUTLOOK

The prominent companies thriving in the companion diagnostics market are Sysmex Corporation, Almac Group, Arup Laboratories, Biocartis, Abbott Laboratories, bioMerieux, GE Healthcare, Genomic Health, Danaher Corporation, Illumina Inc, Myriad Genetics, Qiagen, Roche Diagnostics, Thermo Fisher Scientific, and Agilent.
Abbott Laboratories is a pharmaceutical company engaged in developing and marketing healthcare products. It also offers diagnostic systems, neuro-modulation devices, medical devices, and other products. The company provides these products under multiple brand names, including Similar, Oxepa, Alinity, and FreeStyle, among others. It offers products to consumers, wholesalers, retailers, healthcare facilities, government agencies, laboratories, and ambulatory surgery centers. Abbott operates across North America, Latin America, the Middle and Africa, and Asia-Pacific.

TABLE OF CONTENTS

1. GLOBAL COMPANION DIAGNOSTICS MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY INSIGHTS
2.2.1. COMMERCIAL SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION OF PREDICTIVE BIOMARKERS
2.2.3. FUSION OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY & SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.10. MARKET DRIVERS
2.10.1. INCREASE IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING PREVALENCE OF PRECISION MEDICINES
2.11. MARKET CHALLENGES
2.11.1. WEAK REIMBURSEMENT FRAMEWORK
2.11.2. COMMON CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET OPPORTUNITY
2.12.1. ONGOING RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK – BY MECHANISM
3.1. IN-SITU HYBRIDIZATION
3.2. POLYMERASE CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT GENERATION SEQUENCING
3.5. OTHER MECHANISMS
4. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK – BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS DISEASES
4.4. OTHER INDICATORS
5. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK – BY CONSUMER
5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE LABORATORIES
5.3. OTHER CONSUMERS
6. GLOBAL COMPANION DIAGNOSTICS MARKET OUTLOOK – BY COMMODITY
6.1. ASSAY KITS AND REAGENTS
6.2. SOFTWARE AND SERVICES
7. GLOBAL COMPANION DIAGNOSTICS MARKET – REGIONAL OUTLOOK
7.1. NORTH AMERICA
7.1.1. MARKET OUTLOOK BY MECHANISM
7.1.2. MARKET OUTLOOK BY INDICATOR
7.1.3. MARKET OUTLOOK BY CONSUMER
7.1.4. MARKET OUTLOOK BY COMMODITY
7.1.5. COUNTRY ANALYSIS
7.1.5.1. UNITED STATES
7.1.5.2. CANADA
7.2. EUROPE
7.2.1. MARKET OUTLOOK BY MECHANISM
7.2.2. MARKET OUTLOOK BY INDICATOR
7.2.3. MARKET OUTLOOK BY CONSUMER
7.2.4. MARKET OUTLOOK BY COMMODITY
7.2.5. COUNTRY ANALYSIS
7.2.5.1. UNITED KINGDOM
7.2.5.2. GERMANY
7.2.5.3. FRANCE
7.2.5.4. SPAIN
7.2.5.5. ITALY
7.2.5.6. POLAND
7.2.5.7. REST OF EUROPE
7.3. ASIA-PACIFIC
7.3.1. MARKET OUTLOOK BY MECHANISM
7.3.2. MARKET OUTLOOK BY INDICATOR
7.3.3. MARKET OUTLOOK BY CONSUMER
7.3.4. MARKET OUTLOOK BY COMMODITY
7.3.5. COUNTRY ANALYSIS
7.3.5.1. CHINA
7.3.5.2. JAPAN
7.3.5.3. INDIA
7.3.5.4. SOUTH KOREA
7.3.5.5. ASEAN COUNTRIES
7.3.5.6. AUSTRALIA & NEW ZEALAND
7.3.5.7. REST OF ASIA-PACIFIC
7.4. LATIN AMERICA
7.4.1. MARKET OUTLOOK BY MECHANISM
7.4.2. MARKET OUTLOOK BY INDICATOR
7.4.3. MARKET OUTLOOK BY CONSUMER
7.4.4. MARKET OUTLOOK BY COMMODITY
7.4.5. COUNTRY ANALYSIS
7.4.5.1. BRAZIL
7.4.5.2. MEXICO
7.4.5.3. REST OF LATIN AMERICA
7.5. MIDDLE EAST AND AFRICA
7.5.1. MARKET OUTLOOK BY MECHANISM
7.5.2. MARKET OUTLOOK BY INDICATOR
7.5.3. MARKET OUTLOOK BY CONSUMER
7.5.4. MARKET OUTLOOK BY COMMODITY
7.5.5. COUNTRY ANALYSIS
7.5.5.1. UNITED ARAB EMIRATES
7.5.5.2. SAUDI ARABIA
7.5.5.3. TURKEY
7.5.5.4. SOUTH AFRICA
7.5.5.5. REST OF MIDDLE EAST & AFRICA
8. COMPETITIVE LANDSCAPE
8.1. ABBOTT LABORATORIES
8.2. ALMAC GROUP
8.3. ARUP LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER CORPORATION
8.7. GE HEALTHCARE
8.8. GENOMIC HEALTH
8.9. ILLUMINA INC
8.10. MYRIAD GENETICS
8.11. QIAGEN
8.12. ROCHE DIAGNOSTICS
8.13. SYSMEX CORPORATION
8.14. THERMO FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.2. SOURCES OF DATA
9.3. RESEARCH METHODOLOGY

LIST OF TABLES

TABLE 1: GLOBAL COMPANION DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF CONTRACTS & AGREEMENTS
TABLE 6: NUMBER OF CANCER PATIENTS IN 2020
TABLE 7: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: GLOBAL COMPANION DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 15: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 16: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 17: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 18: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 19: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 20: EUROPE COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 21: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 22: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 23: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 24: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 25: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 26: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 27: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 28: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 29: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 30: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 31: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 32: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 33: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 34: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 35: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 36: MIDDLE EAST AND AFRICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: GLOBAL COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: GLOBAL COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)
FIGURE 8: GLOBAL COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: GLOBAL COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: GLOBAL COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: GLOBAL COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: GLOBAL COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)
FIGURE 19: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: GLOBAL COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: GLOBAL COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)
FIGURE 22: GLOBAL COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 23: GLOBAL COMPANION DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 25: UNITED STATES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: CANADA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 27: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 28: UNITED KINGDOM COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 29: GERMANY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 30: FRANCE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 31: SPAIN COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: ITALY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 33: POLAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 34: REST OF EUROPE COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 35: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 36: CHINA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 37: JAPAN COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 38: INDIA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 39: SOUTH KOREA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 40: ASEAN COUNTRIES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 41: AUSTRALIA & NEW ZEALAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 42: REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 43: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 44: BRAZIL COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 45: MEXICO COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 46: REST OF LATIN AMERICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 47: MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET COUNTRY OUTLOOK, 2021
FIGURE 48: UNITED ARAB EMIRATES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 49: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 50: TURKEY COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 51: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 52: REST OF MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)